AACR 2024: PDC*line Pharma Presents Interim Clinical Results From Last Cohort of Patients in Phase I/II Trial with PDC*lung01 Cancer Vaccine

LIÈGE, Belgium & GRENOBLE, France, April 08, 2024--PDC*line Pharma, a clinical-stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, today announces the interim results from the last cohort of patients in its phase I/II clinical trial (PDC-LUNG-101, NCT03970746) with PDC*lung01.

Related Keywords

France ,Switzerland ,Netherlands ,United States ,South Korea ,Leuven ,Region Flamande ,Belgium ,Poland ,Germany ,French ,Belgian ,American ,Johan Vansteenkiste ,Eric Halioua ,American Association For Cancer Research ,French Blood Bank ,Lg Chem Life Sciences ,Non Small Cell Lung Cancer ,American Association ,Cancer Research ,Annual Meeting ,Low Dose ,High Dose ,Objective Response Rate ,Progression Free Survival ,Partial Response ,Stable Disease ,Best Objective Response ,Disease Control Rate ,Not Reached ,Prof Johan Vansteenkiste ,Safety Monitoring Board ,Beatrice De Vos ,Plasmacytoid Dendritic Cells ,Peripheral Blood Mononuclear Cells ,Life Sciences ,